Susquehanna International Group
XENE icon

Susquehanna International Group’s Xenon Pharmaceuticals XENE Stock Holding History

Susquehanna International Group’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.3M Buy
177,137
+168,818
+2,029% +$7.78M ﹤0.01% 3070
2025
Q4 		$373K Sell
8,319
-37,588
-82% -$1.58M ﹤0.01% 9454
2025
Q3 		$1.84M Sell
45,907
-176,445
-79% -$6.21M ﹤0.01% 5960
2025
Q2 		$6.96M Buy
+222,352
New +$7.25M ﹤0.01% 3384
2024
Q3 		– Sell
-23,036
Closed -$929K – 13177
2024
Q2 		$898K Sell
23,036
-610
-3% -$24.4K ﹤0.01% 6846
2024
Q1 		$1.02M Sell
23,646
-29,305
-55% -$1.35M ﹤0.01% 6876
2023
Q4 		$2.44M Buy
+52,951
New +$1.87M ﹤0.01% 4952
2023
Q3 		– Sell
-8,131
Closed -$304K – 13130
2023
Q2 		$313K Sell
8,131
-7,438
-48% -$296K ﹤0.01% 9345
2023
Q1 		$557K Buy
+15,569
New +$575K ﹤0.01% 8298
2022
Q3 		– Sell
-34,389
Closed -$1.24M – 14245
2022
Q2 		$1.05M Buy
34,389
+14,198
+70% +$429K ﹤0.01% 6431
2022
Q1 		$617K Buy
+20,191
New +$604K ﹤0.01% 8400
2021
Q4 		– Sell
-26,279
Closed -$785K – 14022
2021
Q3 		$402K Sell
26,279
-25,702
-49% -$447K ﹤0.01% 9931
2021
Q2 		$968K Buy
51,981
+25,999
+100% +$479K ﹤0.01% 7866
2021
Q1 		$465K Buy
+25,982
New +$440K ﹤0.01% 9652
2017
Q3 		– Sell
-19,277
Closed -$61K – 9746
2017
Q2 		$61K Buy
+19,277
New +$75.4K ﹤0.01% 8850

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group's XENE Position: Q1 2026 in Review

Susquehanna International Group increased its Xenon Pharmaceuticals (XENE) stake by 2,029% in Q1 2026, buying an estimated $7.78M and bringing the position to 177,137 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3070.

Susquehanna International Group first reported a position in XENE in Q2 2017 and has held it in 15 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Susquehanna International Group held 177,137 shares of Xenon Pharmaceuticals worth $10.3M as of Q1 2026.
  • Susquehanna International Group bought 168,818 Xenon Pharmaceuticals shares in Q1 2026, an estimated $7.78M.
  • Xenon Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3070 holding.
  • Susquehanna International Group first reported a position in Xenon Pharmaceuticals in Q2 2017 and has held it in 15 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.